Mark R. Pittelkow

27.3k total citations · 2 hit papers
366 papers, 19.2k citations indexed

About

Mark R. Pittelkow is a scholar working on Dermatology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Mark R. Pittelkow has authored 366 papers receiving a total of 19.2k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Dermatology, 84 papers in Oncology and 81 papers in Pathology and Forensic Medicine. Recurrent topics in Mark R. Pittelkow's work include Cutaneous lymphoproliferative disorders research (62 papers), Autoimmune Bullous Skin Diseases (40 papers) and Cutaneous Melanoma Detection and Management (28 papers). Mark R. Pittelkow is often cited by papers focused on Cutaneous lymphoproliferative disorders research (62 papers), Autoimmune Bullous Skin Diseases (40 papers) and Cutaneous Melanoma Detection and Management (28 papers). Mark R. Pittelkow collaborates with scholars based in United States, Germany and United Kingdom. Mark R. Pittelkow's co-authors include Gary D. Shipley, Robert E. Scott, Robert J. Coffey, John J. Wille, Dominik Péus, Harold L. Moses, Paul W. Cook, Rik Derynck, Sergei A. Grando and Karin U. Schallreuter and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark R. Pittelkow

358 papers receiving 18.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

2007 926 citations Mark R. Pittelkow et al. profile →
Production and auto-induction of transforming growth factor-α in human keratinocytes

1987 752 citations Mark R. Pittelkow et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark R. Pittelkow United States	77	6.0k	5.3k	4.0k	3.9k	3.5k	366	19.2k
Thomas Ruzicka Germany	81	11.9k 2.0×	5.7k 1.1×	3.2k 0.8×	3.3k 0.9×	6.2k 1.8×	672	26.2k
John Varga United States	75	3.0k 0.5×	6.4k 1.2×	7.6k 1.9×	1.4k 0.4×	3.1k 0.9×	279	20.2k
Brian J. Nickoloff United States	76	5.6k 0.9×	5.3k 1.0×	1.7k 0.4×	4.4k 1.1×	9.1k 2.6×	239	19.0k
John J. Voorhees United States	93	15.8k 2.6×	8.8k 1.7×	2.4k 0.6×	2.5k 0.6×	7.7k 2.2×	420	31.1k
Madeleine Duvic United States	82	14.4k 2.4×	6.7k 1.3×	8.8k 2.2×	5.7k 1.4×	7.9k 2.3×	627	26.2k
Shinichi Sato Japan	80	4.6k 0.8×	4.3k 0.8×	8.9k 2.2×	2.1k 0.5×	8.2k 2.3×	782	25.0k
Juliet N. Barker United States	85	9.0k 1.5×	4.4k 0.8×	2.6k 0.6×	5.1k 1.3×	17.3k 4.9×	559	31.3k
Louis Dubertret France	60	4.1k 0.7×	2.2k 0.4×	2.0k 0.5×	1.1k 0.3×	3.5k 1.0×	368	12.3k
Oliver Distler Switzerland	84	4.2k 0.7×	7.4k 1.4×	12.6k 3.1×	2.0k 0.5×	5.3k 1.5×	610	25.5k
Yoshiki Miyachi Japan	65	5.0k 0.8×	3.8k 0.7×	1.1k 0.3×	1.3k 0.3×	4.6k 1.3×	506	15.9k

Countries citing papers authored by Mark R. Pittelkow

Since Specialization

Citations

This map shows the geographic impact of Mark R. Pittelkow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Pittelkow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Pittelkow more than expected).

Fields of papers citing papers by Mark R. Pittelkow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Pittelkow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Pittelkow. The network helps show where Mark R. Pittelkow may publish in the future.

Co-authorship network of co-authors of Mark R. Pittelkow

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Pittelkow. A scholar is included among the top collaborators of Mark R. Pittelkow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Pittelkow. Mark R. Pittelkow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heil, Peter Maximilian, Mark R. Pittelkow, Amy L. Weaver, et al.. (2024). Systemic correlates of cutaneous manifestations of lupus erythematosus. International Journal of Dermatology. 63(8). e148–e156. 1 indexed citations

Li, Xing, Nan Zhang, Richard Butterfield, et al.. (2024). Topical Ruxolitinib in the Treatment of Necrobiosis Lipoidica: A Prospective, Open-Label Study. Journal of Investigative Dermatology. 144(9). 1994–2001.e4. 3 indexed citations

Butterfield, Richard, Collin M. Costello, William G. Rule, et al.. (2023). Primary cutaneous diffuse large B-cell lymphoma, leg type, presenting as subcutaneous nodules: Case series and comparison of treatment outcomes. JAAD Case Reports. 41. 81–84. 1 indexed citations

Butterfield, Richard, Collin M. Costello, William G. Rule, et al.. (2023). Intralesional and systemic rituximab in the treatment of primary cutaneous B‐cell lymphoma. SHILAP Revista de lepidopterología. 2(4). 872–881. 1 indexed citations

Murphree, Dennis H., Lisa A. Drage, Michael Wang, et al.. (2020). Deep learning for dermatologists: Part I. Fundamental concepts. Journal of the American Academy of Dermatology. 87(6). 1343–1351. 35 indexed citations

Costello, Collin M., et al.. (2020). A case of pediatric lymphomatoid papulosis treated with photodynamic therapy and narrowband ultraviolet B. Pediatric Dermatology. 37(5). 881–883. 3 indexed citations

Le‐Rademacher, Jennifer, Kendrith M. Rowland, Philip J. Atherton, et al.. (2019). Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series. American Journal of Hospice and Palliative Medicine®. 36(6). 519–525. 5 indexed citations

Averbook, Bruce J., Sandra J. Lee, Keith A. Delman, et al.. (2013). Pediatric melanoma: Analysis of an international registry. Cancer. 119(22). 4012–4019. 53 indexed citations

Kadakia, Kunal C., Debra L. Barton, Charles L. Loprinzi, et al.. (2011). Randomized controlled trial of acitretin versus placebo in patients at high‐risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 118(8). 2128–2137. 54 indexed citations

10.

Sekulić, Aleksandar, Su Y. Kim, Galen Hostetter, et al.. (2010). Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma. Cancer Prevention Research. 3(10). 1277–1283. 30 indexed citations

11.

Sekulić, Aleksandar, Paul Haluska, Arlo J. Miller, et al.. (2008). Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape. Mayo Clinic Proceedings. 83(7). 825–846. 90 indexed citations

12.

Eggers, Scott D.Z., et al.. (2007). Acute Carpal Tunnel Syndrome Preceded by 5 Years of Unusual Skin Changes. Archives of Neurology. 64(3). 447–447. 1 indexed citations

13.

Schallreuter, Karin U., et al.. (2007). Structural and functional alterations in the β2‐adrenoceptor are caused by a point mutation in patients with atopic eczema. Experimental Dermatology. 16(10). 807–813. 10 indexed citations

14.

Mehrany, Khosrow, Roger H. Weenig, Mark R. Pittelkow, Randall K. Roenigk, & Clark C. Otley. (2004). High Recurrence Rates of Basal Cell Carcinoma After Mohs Surgery in Patients With Chronic Lymphocytic Leukemia. Archives of Dermatology. 140(8). 985–8. 50 indexed citations

15.

Erickson, Lori A., Jeffrey L. Myers, Martín C. Mihm, Svetomir N. Markovic, & Mark R. Pittelkow. (2004). Malignant Basomelanocytic Tumor Manifesting as Metastatic Melanoma. The American Journal of Surgical Pathology. 28(10). 1393–1396. 37 indexed citations

16.

Mehrany, Khosrow, Lisa A. Drage, David J. Brandhagen, & Mark R. Pittelkow. (2004). Association of porphyria cutanea tarda with hereditary hemochromatosis. Journal of the American Academy of Dermatology. 51(2). 205–211. 22 indexed citations

17.

Brown, Holly, Lawrence E. Gibson, Ramón M. Pujol, John A. Lust, & Mark R. Pittelkow. (2002). Primary follicular mucinosis: Long-term follow-up of patients younger than 40 years with and without clonal T-cell receptor gene rearrangement. Journal of the American Academy of Dermatology. 47(6). 856–862. 54 indexed citations

18.

Péus, Dominik, et al.. (1999). UVB Activates ERK1/2 and p38 Signaling Pathways via Reactive Oxygen Species in Cultured Keratinocytes. Journal of Investigative Dermatology. 112(5). 751–756. 217 indexed citations

19.

Péus, Dominik, et al.. (1997). EGF-Receptor Tyrosine Kinase Inhibition Induces Keratinocyte Growth Arrest and Terminal Differentiation. Journal of Investigative Dermatology. 109(6). 751–756. 141 indexed citations

20.

Zelickson, Brian D., Margot S. Peters, Sigfrid A. Muller, et al.. (1991). T-cell receptor gene rearrangement analysis: Cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders. Journal of the American Academy of Dermatology. 25(5). 787–796. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact